Clinical Trials Sponsored by Fundacion iSYS

Total 17505 results

Fundacion Clinic per a la Recerca Biomédica
Fundacion iSYS, internet, salud y sociedad

Completed

Evaluation of the Impact of a Multidimensional ICT Intervention on the Quality of Life of Breast Cancer Survivors

Quality of Life | Breast Cancer | Breast Neoplasms | Survivorship

Spain
INSYS Therapeutics Inc

Completed

Study of Buprenorphine Sublingual Spray Versus Standard of Care Narcotic Therapy for the Treatment of Post-Operative Pain

Pain, Postoperative

United States
INSYS Therapeutics Inc

Completed

Cannabidiol Oral Solution as an Adjunctive Treatment for Treatment-resistant Seizure Disorder

Seizures

United States
INSYS Therapeutics Inc

Completed

Fentanyl Sublingual Spray for the Treatment of Moderate to Severe Post-Operative Pain

Pain

United States
INSYS Therapeutics Inc

Completed

Study of Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Pain

United States
INSYS Therapeutics Inc

Completed

Cannabidiol Oral Solution in Pediatric Participants With Treatment-resistant Seizure Disorders

Seizures

United States
INSYS Therapeutics Inc

Completed

Exploratory Bioavailability of Fentanyl Sublingual Spray Under Fasting Conditions

Bioavailability

United States
INSYS Therapeutics Inc

Withdrawn

Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: IV Infusion QOD x Six Doses

Neoplasms

United States
INSYS Therapeutics Inc

Completed

Liposome Encapsulated SN38 (LE-SN38) in Patients With Advanced Cancer

Neoplasms

United States
INSYS Therapeutics Inc

Completed

Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Cancer

Neoplasms

United States
INSYS Therapeutics Inc

Completed

Comparison of Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) and Taxol® Pharmacokinetics in Patients With Advanced Cancer

Neoplasm

United States, Germany, Netherlands
INSYS Therapeutics Inc

Completed

A Study to Compare Bioavailability of Naloxone Nasal Spray and Naloxone Hydrochloride (HCl) Intramuscular Injection (IM) in Healthy Volunteers

Healthy Volunteer

United States
INSYS Therapeutics Inc

Completed

A Study to Compare Bioavailability of Naloxone Nasal Spray, Naloxone Hydrochloride (HCl) Intravenous (IV) and Intramuscular Injection (IM) in Healthy Volunteers

Healthy Volunteer

United States
INSYS Therapeutics Inc

Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

Dravet Syndrome
INSYS Therapeutics Inc

Terminated

Buprenorphine Sublingual Spray for the Treatment of Moderate to Severe Pain

Post-operative Pain

United States
INSYS Therapeutics Inc

Withdrawn

Study to Explore Effectiveness of Sublingual Fentanyl Spray in Emergency Department Patients With Acute Pain

Acute Pain

United States
INSYS Therapeutics Inc

Completed

Comparative Bioavailability of Dronabinol Oral Solution in Healthy Volunteers

Healthy

United States
INSYS Therapeutics Inc

Completed

Fentanyl Sublingual Spray and Fentanyl Citrate Intravenous (IV) in Opioid Naive Subjects

Pharmacokinetics and Pharmacodynamics

United States
INSYS Therapeutics Inc

Withdrawn

Study of SS1(dsFv)-PE38 (SS1P) Anti-Mesothelin Immunotoxin in Advanced Malignancies: Continuous Infusion for 10 Days

Neoplasms

United States
INSYS Therapeutics Inc

Completed

Long-term Safety and Efficacy Study of Fentanyl Sublingual Spray for the Treatment of Breakthrough Cancer Pain

Pain | Cancer

United States, India, Canada
INSYS Therapeutics Inc

Completed

Pharmacokinetic Study of Fentanyl 400 µg Sublingual Spray, Actiq® 400 µg Transmucosally, and Fentanyl Citrate Injection 100 µg Intravenously (iv)

Pain

United States
INSYS Therapeutics Inc

Completed

Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer

Breast Cancer

India
INSYS Therapeutics Inc

Completed

Comparative Bioavailability of Dronabinol Oral Solution Versus Branded Capsule 5 mg Under Fasting Conditions

Bioavailability

United States
INSYS Therapeutics Inc

Completed

Pre-operative IL13-PE38QQR in Patients With Recurrent or Progressive Malignant Glioma

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Mixed Oligoastrocytoma

United States, Germany, Israel
ISIS Diabete Service

Unknown

Intensive Versus Standard One Year Monitoring on Glycaemic Control After Initiating CSII in Children With DT1. DEEP Study (DEEP)

Diabetes Mellitus, Type 1 | Pediatric ALL

France
INSYS Therapeutics Inc

Terminated

Cannabidiol Oral Solution for Treatment of Refractory Infantile Spasms

Spasms, Infantile

United States
INSYS Therapeutics Inc

Withdrawn

Efficacy and Safety Study of LE-DT to Treat Metastatic Castrate Resistant Prostate Cancer

Prostate Cancer

United States
INSYS Therapeutics Inc

Withdrawn

Fentanyl Sublingual Spray for the Treatment of Acute Procedure-related Pain in a Monitored Setting

Chronic Pain
INSYS Therapeutics Inc

Withdrawn

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Lennox-Gastaut Syndrome

Lennox-Gastaut Syndrome
INSYS Therapeutics Inc

Completed

Fentanyl Sublingual Spray in Opioid Naive Participants

Pharmacology

United States
INSYS Therapeutics Inc

Completed

Study of Buprenorphine-Naloxone Sublingual Spray and Suboxone® Sublingual Film in Healthy Volunteers

Opiate Dependence

United States
INSYS Therapeutics Inc

Completed

Interstitial Infusion of IL13-PE38QQR Cytotoxin in Recurrent Malignant Glioma

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Mixed Oligoastrocytoma

United States
INSYS Therapeutics Inc

Completed

A Study of the Abuse Potential of Dronabinol in Recreational Cannabinoid Users

Drug Abuse, Medication

Canada
INSYS Therapeutics Inc

Completed

Fentanyl Sublingual Spray in Treating Opioid-tolerant Cancer Patients With or Without Oral Mucositis

Pain | Unspecified Adult Solid Tumor, Protocol Specific | Mucositis

United States
INSYS Therapeutics Inc

Completed

Efficacy and Safety Study of LE-DT to Treat Locally Advanced or Metastatic Pancreatic Cancer

Pancreatic Cancer

United States
INSYS Therapeutics Inc

Completed

Liposome Encapsulated Docetaxel (LE-DT) in Patients With Solid Tumors (LE-DT)

Solid Tumors

United States
INSYS Therapeutics Inc

Completed

IL13-PE38QQR Infusion After Tumor Resection, Followed by Radiation Therapy With or Without Temozolomide in Patients With Newly Diagnosed Malignant Glioma

Glioblastoma Multiforme | Oligoastrocytoma | Anaplastic Astrocytoma

United States
INSYS Therapeutics Inc

Completed

Liposome Entrapped Paclitaxel Easy to Use (LEP-ETU) in Patients With Advanced Cancer

Neoplasm

United States
INSYS Therapeutics Inc

Completed

Imaging Study of the Distribution of IL13-PE38QQR Infused Before and After Surgery in Adult Patients With Recurrent Malignant Glioma

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Anaplastic Oligodendroglioma | Mixed Oligoastrocytoma

United States
INSYS Therapeutics Inc

Completed

The PRECISE Trial: Study of IL13-PE38QQR Compared to GLIADEL Wafer in Patients With Recurrent Glioblastoma Multiforme

Glioblastoma Multiforme

United States, Canada, United Kingdom, Germany, Israel, Netherlands
INSYS Therapeutics Inc

Completed

Study of Liposome Encapsulated Mitoxantrone (LEM) in Patients With Advanced Cancer

Tumors

United States
INSYS Therapeutics Inc

Completed

Histologic Effect/Safety of Pre/Post-Operative IL13-PE38QQR in Recurrent Resectable Supratentorial Malignant Glioma Patients

Glioblastoma Multiforme | Malignant Glioma | Anaplastic Astrocytoma | Mixed Oligoastrocytoma | Malignant Astrocytoma

United States
INSYS Therapeutics Inc
Georgetown University

Completed

Study to Determine Maximum Tolerated Dose of LErafAON Combined With Radiotherapy in Patients With Advanced Malignancies

Neoplasms

United States
INSYS Therapeutics Inc
Georgetown University

Completed

Study to Determine the Maximum Tolerated Dose of LErafAON in Patients With Advanced Solid Tumors

Neoplasms

United States
Santersus AG
ISS AG

Not yet recruiting

Safety, Tolerability and Performance of the NucleoCapture Device in the Reduction of Circulating cfDNA/NETs in Subjects With Sepsis (NUC-CAP)

Sepsis | Respiratory Failure

United Kingdom, Germany, Switzerland
SynDermix AG
ISS AG

Withdrawn

Safety and Efficacy of SDX-3101 for the Treatment of Chronic Rhinosinusitis Without Nasal Polyps (CRSsNP) (SDX-3101)

Chronic Rhinosinusitis Without Nasal Polyps

Germany, Austria, Switzerland
University of Chicago
INSYS Therapeutics Inc

Completed

Cannabidiol and Emotional Stimuli (CAS)

Drug Addiction

United States
M.D. Anderson Cancer Center
INSYS Therapeutics Inc

Terminated

Sublingual Fentanyl for the Management of Breakthrough Pain

Advanced Cancers

United States
M.D. Anderson Cancer Center
INSYS Therapeutics Inc

Completed

Fentanyl Sublingual Spray for Exercise-Induced Breakthrough Dyspnea

Advanced Cancers

United States
INSYS Therapeutics Inc
National Cancer Institute (NCI)

Completed

Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain

Cancer

United States

3

Subscribe